studies

mML - 1st line (L1), ... vs. ..., meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 1.82 [1.39; 2.38] CheckMate 069 (all population), 2015 (REV) 1.35 [0.79; 2.31] CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV) 0.69 [0.22; 2.17] 1.50[1.02; 2.21]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV)338%804lownot evaluable deaths (OS) (extension)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 1.92 [1.56; 2.37] 1.92[1.56; 2.37]CheckMate 067 (NI vs I ; all population), 2015 (REV)10%629NAnot evaluable PFS (extension)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 2.38 [1.97; 2.87] CheckMate 069 (all population), 2015 (REV) 2.78 [1.74; 4.43] CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV) 2.14 [0.44; 10.39] 2.43[2.04; 2.89]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV)30%804lownot evaluable progression or deaths (PFS)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 2.38 [1.76; 3.23] CheckMate 069 (all population), 2015 (REV) 2.63 [1.59; 4.36] CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV) 2.63 [1.02; 6.79] CheckMate 069 (BRAF wild type), 2015 (REV) 2.50 [1.45; 4.30] 2.47[1.96; 3.10]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV), CheckMate 069 (BRAF wild type), 2015 (REV)40%913lownot evaluable objective responses (ORR)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.16 [0.10; 0.28] CheckMate 069 (all population), 2015 (REV) 0.07 [0.04; 0.12] CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV) 0.10 [0.00; 2.21] CheckMate 069 (BRAF wild type), 2015 (REV) 0.08 [0.02; 0.29] 0.10[0.06; 0.18]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV), CheckMate 069 (BRAF wild type), 2015 (REV)439%913lownot evaluable objective responses (ORR) (extension)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.16 [0.11; 0.23] CheckMate 069 (all population), 2015 (REV) 0.08 [0.03; 0.23] CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV) 0.10 [0.00; 2.20] CheckMate 069 (BRAF wild type), 2015 (REV) 0.08 [0.02; 0.29] 0.14[0.10; 0.19]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 (REV), CheckMate 069 (BRAF wild type), 2015 (REV)40%913lownot evaluable TRAE (any grade)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.27 [0.14; 0.51] CheckMate 069 (all population), 2015 (REV) 1.33 [0.34; 5.28] 0.53[0.11; 2.50]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)276%764lownot evaluable TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.26 [0.19; 0.37] CheckMate 069 (all population), 2015 (REV) 0.26 [0.12; 0.58] 0.26[0.19; 0.36]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable TRAE leading to death (grade 5)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88] 1.01[0.02; 50.88]CheckMate 067 (NI vs I ; all population), 2015 (REV)10%624NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.25 [0.17; 0.37] CheckMate 069 (all population), 2015 (REV) 0.24 [0.10; 0.57] CheckMate 069 (BRAF wild type), 2015 (REV) 0.30 [0.12; 0.71] 0.25[0.18; 0.35]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV), CheckMate 069 (BRAF wild type), 2015 (REV)30%872lownot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.37 [0.25; 0.55] CheckMate 069 (all population), 2015 (REV) 0.24 [0.09; 0.63] 0.35[0.24; 0.50]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Abdominal pain TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 2.02 [0.18; 22.39] CheckMate 069 (all population), 2015 (REV) 4.16 [0.14; 126.20] 2.57[0.36; 18.33]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.02; 1.38] CheckMate 069 (all population), 2015 (REV) 4.23 [0.37; 47.88] 0.79[0.03; 18.93]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)274%764lownot evaluable Arthralgia TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.25 [0.01; 5.58] CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24] 0.56[0.05; 6.42]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Asthenia TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 2.02 [0.18; 22.39] CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24] 2.03[0.26; 15.80]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Chills TRAE (grade 3-4)detailed resultsCheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24] 2.05[0.04; 105.24]CheckMate 069 (all population), 2015 (REV)10%140NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.92 [0.52; 1.65] CheckMate 069 (all population), 2015 (REV) 0.34 [0.09; 1.23] 0.67[0.27; 1.67]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)248%764lownot evaluable Constipation TRAE (grade 3-4)detailed resultsCheckMate 069 (all population), 2015 (REV) 1.02 [0.03; 31.03] 1.02[0.03; 31.03]CheckMate 069 (all population), 2015 (REV)10%140NAnot evaluable Cough TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88] 1.01[0.02; 50.88]CheckMate 067 (NI vs I ; all population), 2015 (REV)10%624NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.25 [0.03; 2.24] CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24] 0.41[0.06; 2.80]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.60 [0.33; 1.11] CheckMate 069 (all population), 2015 (REV) 1.02 [0.33; 3.19] 0.68[0.40; 1.16]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Dry skin TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88] 1.01[0.02; 50.88]CheckMate 067 (NI vs I ; all population), 2015 (REV)10%624NAnot evaluable Dyspnoea TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.01; 3.34] CheckMate 069 (all population), 2015 (REV) 0.33 [0.02; 6.80] 0.24[0.03; 1.97]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Endocrine disorders TRAE (grade 3-4) detailed resultsCheckMate 069 (all population), 2015 (REV) 0.81 [0.15; 4.34] 0.81[0.15; 4.34]CheckMate 069 (all population), 2015 (REV)10%140NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.22 [0.06; 0.80] CheckMate 069 (all population), 2015 (REV) 0.20 [0.01; 3.66] 0.22[0.07; 0.70]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed resultsCheckMate 069 (all population), 2015 (REV) 0.45 [0.16; 1.29] 0.45[0.16; 1.29]CheckMate 069 (all population), 2015 (REV)10%140NAnot evaluable Headache TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.05; 5.56] CheckMate 069 (all population), 2015 (REV) 0.51 [0.02; 11.44] 0.50[0.07; 3.38]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Hepatitis TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.10 [0.01; 1.82] CheckMate 069 (all population), 2015 (REV) 0.33 [0.02; 6.80] 0.18[0.02; 1.45]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed resultsCheckMate 069 (all population), 2015 (REV) 0.06 [0.00; 1.08] 0.06[0.00; 1.08]CheckMate 069 (all population), 2015 (REV)10%140NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.01; 3.34] CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24] 0.42[0.04; 4.55]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 1.01 [0.29; 3.51] CheckMate 069 (all population), 2015 (REV) 2.09 [0.29; 15.34] 1.24[0.43; 3.57]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03] CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24] 0.92[0.07; 12.01]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Increase AST TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.10 [0.02; 0.43] CheckMate 069 (all population), 2015 (REV) 0.14 [0.01; 2.46] 0.11[0.03; 0.39]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Increased ALT TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.07; 0.46] CheckMate 069 (all population), 2015 (REV) 0.09 [0.01; 1.62] 0.16[0.06; 0.41]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Increased lipase level TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.33 [0.17; 0.65] CheckMate 069 (all population), 2015 (REV) 0.24 [0.03; 1.97] 0.32[0.17; 0.61]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.02; 1.38] CheckMate 069 (all population), 2015 (REV) 0.33 [0.02; 6.80] 0.21[0.04; 1.18]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Myalgia TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03] CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24] 0.92[0.07; 12.01]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Nausea TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.28 [0.06; 1.37] CheckMate 069 (all population), 2015 (REV) 2.07 [0.13; 33.80] 0.54[0.09; 3.35]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)232%764lownot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.33 [0.03; 3.22] CheckMate 069 (all population), 2015 (REV) 1.02 [0.09; 11.57] 0.56[0.11; 2.95]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Pruritic rash TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88] CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24] 1.44[0.09; 23.12]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Pruritus TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.17 [0.02; 1.38] CheckMate 069 (all population), 2015 (REV) 1.02 [0.03; 31.03] 0.27[0.05; 1.66]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Pyrexia TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.05; 5.56] CheckMate 069 (all population), 2015 (REV) 0.33 [0.02; 6.80] 0.43[0.07; 2.81]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Rash TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.17; 1.47] CheckMate 069 (all population), 2015 (REV) 0.20 [0.01; 3.66] 0.44[0.16; 1.22]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Renal and urinary disorders TRAE (grade 3-4) detailed resultsCheckMate 069 (all population), 2015 (REV) 1.02 [0.03; 31.03] 1.02[0.03; 31.03]CheckMate 069 (all population), 2015 (REV)10%140NAnot evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed resultsCheckMate 069 (all population), 2015 (REV) 0.67 [0.07; 6.66] 0.67[0.07; 6.66]CheckMate 069 (all population), 2015 (REV)10%140NAnot evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed resultsCheckMate 069 (all population), 2015 (REV) 0.10 [0.01; 1.83] 0.10[0.01; 1.83]CheckMate 069 (all population), 2015 (REV)10%140NAnot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.50 [0.02; 15.03] 0.50[0.02; 15.03]CheckMate 067 (NI vs I ; all population), 2015 (REV)10%624NAnot evaluable Vitiligo TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 1.01 [0.02; 50.88] CheckMate 069 (all population), 2015 (REV) 2.05 [0.04; 105.24] 1.44[0.09; 23.12]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Vomiting TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 0.14 [0.02; 1.15] CheckMate 069 (all population), 2015 (REV) 1.02 [0.03; 31.03] 0.24[0.04; 1.45]CheckMate 067 (NI vs I ; all population), 2015 (REV), CheckMate 069 (all population), 2015 (REV)20%764lownot evaluable Weight decreased TRAE (grade 3-4)detailed resultsCheckMate 067 (NI vs I ; all population), 2015 (REV) 2.02 [0.07; 60.32] 2.02[0.07; 60.32]CheckMate 067 (NI vs I ; all population), 2015 (REV)10%624NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-07-27 05:27 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 285,68,127,128 - treatments: 329

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons